CABACabaletta Bio, Inc.
$1.94-16% 1Y
$1.94
$1.8852 weeks$4.15
CABA in its own filings
Nothing in CABA's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
148
Events found in the filings · across 444 filings · the record starts in 2019
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 14, 2026
Most recent filing · Form 8-K
- Record starts
- Aug 28, 2019
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 9, 2026
- SEC comment-letter activity13 occurrences
- 2025-08-13
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 14, 2026In connection with Cabaletta Bio’s (the “Corporation”) June 2025 underwritten public offering, the Corporation issued 53,090,190 common stock warrants (the “Common Stock Warrants”) that had an exercise price of $2.50 per whole share of its common stock and an expiration date of September 12, 2026 (the “Expiration …Other event · Form 8-K
- Aug 13, 2026Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Jun 11, 2026On June 9, 2026, Cabaletta Bio, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”)Charter/bylaw amendment or fiscal-year change · Form 8-K
- Jun 3, 2026On June 3, 2026, the Company posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation (the “Corporate Presentation”)Regulation FD disclosure · Form 8-K
- May 14, 2026Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- May 14, 2026On May 14, 2026, the Company posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation (the “Corporate Presentation”)Regulation FD disclosure · Form 8-K
- May 4, 2026On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. (collectively, the “Underwriters”), relating to an underwritten registered direct offering (the “Offering”) of …Material agreement entered · Form 8-K
- May 4, 2026Cabaletta intends to present new clinical and translational data from 4 refractory patients that received rese-cel at the lowest dose without preconditioning in the RESET-PV ® (pemphigus vulgaris) trial at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, being held on May 14, 2026.Other event · Form 8-K
- Apr 20, 2026On April 20, 2026, Cabaletta Bio, Inc. (the “Company”) posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation (the “Corporate Presentation”)Other event · Form 8-K
- Mar 23, 2026Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update.Earnings release · press release
- Jan 12, 2026On January 12, 2026, the Company posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation (the “Corporate Presentation”)Regulation FD disclosure · Form 8-K
- Nov 10, 2025Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…